Showing 4721-4730 of 9330 results for "".
- Melanoma Rates Up as Overall US Cancer Incidence Fallshttps://practicaldermatology.com/news/20130123-melanoma_rates_up_as_overall_us_cancer_incidence_falls/2459629/While incidence rates are declining for most cancer sites, they are increasing among both men and women for melanoma of the skin and cancers of the liver, thyroid, and pancreas. Overall cancer incidence rates decreased slightly in males (by 0.6% per year) and were stable in females in the most rece…
- Provectus Pharmaceuticals to Present on PV-10 at AACRhttps://practicaldermatology.com/news/20130123-provectus_pharmaceuticals_to_present_on_pv-10_at_aacr/2459631/Provectus Pharmaceuticals, Inc. will present data on PV-10 in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination of PV-10 immuno-chemoablation and systemic anti-CT…
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 per share. The acquisition is expected to close late in the first or second quarter of 2013.
- BOTOX Receives FDA Approval for Overactive Bladderhttps://practicaldermatology.com/news/20130121-botox_receives_fda_approval_for_overactive_bladder/2459633/The US FDA just approved BOTOX (onabotulinumtoxinA) from Allergan, Inc. for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication. In two double…
- Candescent Partners Buys Dermatology Associates of Tylerhttps://practicaldermatology.com/news/20130114-candescent_partners_buys_dermatology_associates_of_tyler/2459638/Candescent Partners, a Boston-based private equity firm, acquired Dermatology Associates of Tyler. Candescent led the transaction with co-investors Eagle Private Capital and Harbert Mezzanine Partners. Dermatology Associates provides medical and cosmetic dermatological services in the Eastern Texa…
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM 1 & 2 Phase 3 studies. ESTEEM 1 & 2 are the two pivotal Pha…
- Winter Rosacea Treatmentshttps://practicaldermatology.com/news/20130108-winter_rosacea_treatments/2459646/Winter weather and the associated heating systems can easily aggravate sensitive and rosacea-prone skin. With Rosacea Awareness Month coming up this April, the following products can help sooth and calm the redness and irritation associated with rosacea. Dermelect Redness Rehab Rosacea Relief he…
- DermOne Acquires Atlantic Dermatologyhttps://practicaldermatology.com/news/20130107-dermone_acquires_atlantic_dermatology/2459647/DermOne closed on the acquisition of Atlantic Dermatology of Wilmington, NC on December 31, 2012. Atlantic Dermatology specializes in cosmetic, laser, medical, and surgical dermatology. Atlantic was founded by Dr. Jonathan Crane, who will continue to lead the practice in Wilmington but will also jo…
- Valeant Pharmaceuticals Appoints New Managementhttps://practicaldermatology.com/news/20130103-valeant_pharmaceuticals_appoints_new_management/2459649/Valeant Pharmaceuticals International, Inc. named Laizer D. Kornwasser the Executive Vice President/Company Group Chairman, where he will be responsible for operations in Canada, US Neurology, and managed care and distribution, effective February 1, 2013. Previously, Mr. Kornwasser was a Senior Exe…
- Perrigo Company Acquires Cobrek Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130102-perrigo_company_acquires_cobrek_pharmaceuticals_inc/2459651/Perrigo Company signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, Inc. for approximately $45 million on a cash-free and debt-free basis. The merge concludes a four-year collaborative partnership responsible for the successful launches of generic versions …